Literature DB >> 26071011

Bilateral Pheochromocytomas in MEN2A Syndrome: A Two-Institution Experience.

Brian Hung-Hin Lang1, Hyeong Won Yu, Chung-Yau Lo, Kyu Eun Lee, Maria-Mercedes Garcia-Barcelo, Yu Cho Woo, Paul C H Lee, Kai Pun Wong, Paul K H Tam, Karen S L Lam.   

Abstract

BACKGROUND: Bilateral pheochromocytoma (PHEO) is more frequently found in patients with multiple endocrine neoplasia 2A carrying a RET germline mutation located in codon 634 (C634). However, it is unclear whether different amino acid substitutions within C634 cause differences in bilateral PHEOs expression. We aimed to answer this by pooling data from two Asian institutions.
METHODS: Sixty-seven patients had confirmed C634 germline mutation. Age-dependent penetrance of bilateral PHEO was calculated from date of birth to the date when bilateral PHEO was first diagnosed or when the contralateral gland became a PHEO (if the patient already had one adrenal gland removed). Age-dependent penetrance was estimated by the Kaplan-Meier method and compared by log-rank test.
RESULTS: The 4 different amino acid substitutions included C634R (arginine) (n = 19, 28.4 %), C634Y (tyrosine) (n = 36, 38.8 %), C634G (glycine) (n = 4, 6.0 %), and C634W (tryptophan) (n = 8, 11.9 %). The age-related penetrance of PHEO was similar between C634R, C634Y, C634G, and C634W (by age 40, 69.8, 55.2, 25.0, and 56.2 %, respectively) (p = 0.529). However, the age-related penetrance of bilateral PHEO in C634R was significantly higher than C634Y (by age of 40, 59.3 % vs. 25.2 %, p = 0.046) or C634Y, C634G, and C634W combined (59.3 % vs. 21.5 %, p = 0.024). Nevertheless, the accumulative risk of bilateral PHEOs across all four C634 mutations almost approached 100 % over time.
CONCLUSION: The accumulative risk of bilateral PHEOs almost reached 100 % but its onset was significantly earlier in C634R mutation. These findings implied that those with C634R mutation might benefit from earlier screening of contralateral PHEO than other C634 mutations after an unilateral adrenalectomy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26071011     DOI: 10.1007/s00268-015-3117-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

Review 1.  Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A.

Authors:  Reza Asari; Christian Scheuba; Klaus Kaczirek; Bruno Niederle
Journal:  Arch Surg       Date:  2006-12

2.  Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.

Authors:  Ioana N Milos; Karin Frank-Raue; Nelson Wohllk; Ana Luiza Maia; Eduardo Pusiol; Attila Patocs; Mercedes Robledo; Josefina Biarnes; Marta Barontini; Thera P Links; Jan Willem de Groot; Sarka Dvorakova; Mariola Peczkowska; Lisa A Rybicki; Maren Sullivan; Friedhelm Raue; Ioana Zosin; Charis Eng; Hartmut P H Neumann
Journal:  Endocr Relat Cancer       Date:  2008-09-15       Impact factor: 5.678

3.  Role of RET genetic variants in MEN2-associated pheochromocytoma.

Authors:  Débora Rodrigues Siqueira; Lucieli Ceolin; Carla Vaz Ferreira; Mírian Romitti; Silvana Cavalcante Maia; Léa Maria Zanini Maciel; Ana Luiza Maia
Journal:  Eur J Endocrinol       Date:  2014-03-10       Impact factor: 6.664

4.  High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients.

Authors:  Tsuneo Imai; Shinya Uchino; Takahiro Okamoto; Shinichi Suzuki; Shinji Kosugi; Toyone Kikumori; Akihiro Sakurai
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

5.  Resection of phaeochromocytoma extending into the right atrium in a patient with multiple endocrine neoplasia type 2A.

Authors:  C F Ku; C Y Lo; W F Chan; S W Chiu; S T Fan; K S L Lam
Journal:  Hong Kong Med J       Date:  2005-02       Impact factor: 2.227

6.  Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2.

Authors:  Andreas Machens; Michael Brauckhoff; Hans-Jürgen Holzhausen; Phuong Nguyen Thanh; Hendrik Lehnert; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

7.  RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome.

Authors:  Marcia K Puñales; Hans Graf; Jorge L Gross; Ana Luiza Maia
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

8.  Pheochromocytoma in MEN 2A syndrome. Study of 54 patients.

Authors:  Jose M Rodriguez; Maria Balsalobre; Jose L Ponce; Antonio Ríos; Nuria M Torregrosa; Javier Tebar; Pascual Parrilla
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

9.  The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.

Authors:  Sonali Thosani; Montserrat Ayala-Ramirez; Lynn Palmer; Mimi I Hu; Thereasa Rich; Robert F Gagel; Gilbert Cote; Steven G Waguespack; Mouhammed Amir Habra; Camilo Jimenez
Journal:  J Clin Endocrinol Metab       Date:  2013-09-12       Impact factor: 5.958

10.  Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing.

Authors:  Gregory S K Lau; Brian H H Lang; C Y Lo; Annette Tso; Merce M Garcia-Barcelo; Paul K Tam; Karen S L Lam
Journal:  Hong Kong Med J       Date:  2009-10       Impact factor: 2.227

View more
  4 in total

1.  Genotype-Phenotype Correlation in Indian Patients with MEN2-Associated Pheochromocytoma and Comparison of Clinico-Pathological Attributes with Apparently Sporadic Adrenal Pheochromocytoma.

Authors:  Sendhil Rajan; Ghazala Zaidi; Gaurav Agarwal; Anjali Mishra; Amit Agarwal; Saroj Kanta Mishra; Eesh Bhatia
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

2.  RET c.1901G>A and Novel SLC12A3 Mutations in Familial Pheochromocytomas.

Authors:  Lin Zhao; Kun-Qi Yang; Peng Fan; Ding-Xu Gong; Lin Zhang; Yi-Ting Lu; Xu Meng; Xian-Liang Zhou
Journal:  Genes (Basel)       Date:  2022-05-12       Impact factor: 4.141

3.  Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).

Authors:  Ji-Young Lee; Su Yeon Kim; Kwan Hoon Jo; Eun Yeong Mo; Eun Sook Kim; Hye Soo Kim; Je Ho Han; Sung-Dae Moon
Journal:  Korean J Intern Med       Date:  2021-12-15       Impact factor: 3.165

4.  The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A.

Authors:  Zheng Yang; Xinmeng Qi; Neil Gross; Xiujuan Kou; Yunlong Bai; Yaru Feng; Bochun Wang; Mark E Zafereo; Guojun Li; Chuanzheng Sun; Huihui Li; Xiaohong Chen; Zhigang Huang
Journal:  J Cell Mol Med       Date:  2020-09-29       Impact factor: 5.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.